U.S. Markets open in 2 hrs 35 mins

OncoCyte Corporation (OCX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.2900+0.0900 (+4.09%)
At close: 04:00PM EST
2.2900 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2000
Bid0.0000 x 2200
Ask0.0000 x 1000
Day's Range2.1550 - 2.3000
52 Week Range1.9200 - 6.5700
Avg. Volume431,348
Market Cap205.799M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.3700
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.67
  • GlobeNewswire

    Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021

    Spotlight poster presentation indicates DetermaIO assay and algorithm is robust across multiple diagnostic platforms, confirms that test predicts response to immunotherapy (atezolizumab) benefit Oncocyte will support a Continuing Medical Education event on Immunotherapy Biomarkers at SABCS, hosting key opinion leaders from the United States and Europe IRVINE, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve

  • Simply Wall St.

    Is OncoCyte (NASDAQ:OCX) Using Too Much Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other biomarkers DetermaIO data in Triple Negative Breast Cancer published in a peer reviewed journal and confirmed in a randomized clinical trial study presented at ESMO; Evidence in fourth tumor type suggests pan-cancer utility DetermaRx test volume grows 65% year over year US transplant IP issued supp